Summary: No antiviral has been shown to reduce mortality in SARS-COV-2 patients to date. In the present observational and retrospective report, 3,099 patients with a definitive or highly probable diagnosis of infection due to COVID-19 were evaluated between May 1st to August 10th, 2020, at Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC), and all received compassionate treatment with Ivermectin. A total of 2,706 (87.3%) were discharged for outpatient treatment, all with mild severity of the infection. In 2,688 (99.33%) with outpatient treatment, the disease did not progress to warrant further hospitalization and there were no deaths. In 16 (0.59%) with outpatient treatment, it was necessary their subsequent hospitalization to a room without any death. In 2 (0.08%) with outpatient treatment, it was necessary their admission to the Intensive Care Unit (ICU) and 1 (0.04%) patient died. There were 411 (13.3%) patients hospitalized, being admitted at a COVID-19 room with a moderate disease 300 (9.7%) patients of which 3 (1%) died; and with a severe to critical disease were hospitalized in the ICU 111 (3.6%), 34 (30.6%) of whom died. The mortality percentage of patients admitted to the ICU of 30.6%, is similar with the percentage found in the literature of 30.9%. Total mortality was 37 (1.2%) patients, which is much lower than that reported in world statistics, which are around 3%.
This observational and retrospective cohort study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly oral (PO) dose of 0.2 mg/kg, is an effective pre-exposure prophylaxis (PrEP) method for the spread of Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2), in the healthcare workers.
The study began on June 29, 2020 and ended on July 26, 2020, where 713 active healthcare personnel were included for the analysis, of which 326 adhered to a weekly prophylactic program with Ivermectin for Coronavirus Disease-19 (COVID-19), designed by Grupo Rescue task force, that runs both medical centers, and 387 healthcare personnel who did not adhere to the program were assigned to the control group. A SPSS Propensity Score Matching procedure was applied in a 1:1 ratio to homogeneously evaluate the groups that were made up of 271 participants each.
In 28 days of follow-up, a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed 1.8% compared to those who did not take it 6.6%, (p-value = 0.006) and a reduction of the risk of a positive Chain Reaction of Real-Time Polymerase Transcription (RT-PCR) COVID-19 test by 74% (HR 0.26, 95% CI [0.10,0.71]). These results support the use of weekly Ivermectin as a compassionate preventive method in the healthcare personnel.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.